Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.43 |
| ▸ | PRKCI | P41743 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 3/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | LTK | P29376 | 2/20 | 0.36 |
| ▸ | GRK5 | P34947 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22960022 | 0.83 | CIT (0.42) | NUDT1PRKCIAXLGPR84ROCK2 | |
| SCHEMBL13980964 | 0.77 | MET (0.51) | CDK8JAK3CITMET | |
| SCHEMBL2888017 | 0.77 | ROCK2 (0.48) | PRKCIAXLROCK2DAPK3PRKD3 | |
| SCHEMBL2888351 | 0.76 | ROCK2 (0.67) | AXLROCK2CSF1RDAPK3PRKACA | |
| SCHEMBL2887558 | 0.75 | ADRA2B (0.39) | ADRA2BAXLROCK2CSF1RDAPK3 | |
| SCHEMBL2886384 | 0.75 | ROCK2 (0.38) | NUDT1PRKCIROCK2CSF1RDAPK3 | |
| SCHEMBL13981042 | 0.75 | CIT (0.48) | CITMETFLT3 | |
| SCHEMBL13980993 | 0.75 | MET (0.52) | JAK3CITMETFLT3 | |
| SCHEMBL8272276 | 0.74 | ROCK2 (0.68) | ROCK2 | |
| SCHEMBL14907863 | 0.74 | NUDT1 (0.37) | ADRA2BNUDT1PRKCIAXLROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | ADRA2B 729/4885NUDT1 5/4885PRKCI 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.